http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Pediatric Cancer Research using Healthcare Big Data
Hyery Kim 대한소아혈액종양학회 2022 Clinical Pediatric Hematology-Oncology Vol.29 No.1
Health insurance big data provides real-world evidence of unmet needs in clinical practice and breakthroughs in the medical industry that will impact the future of health care. Big data is expected to revolutionize the current medical paradigm and usher in an era of personalized medicine. In Korea, the Health Insurance Review and Assessment Service and the National Health Insurance Service established large-ca-pacity healthcare big data open systems in 2011 and 2013, respectively, and are pro-viding researchers with secured healthcare big data. However, concerns have been raised regarding the quality of big data-based research. Thus, numerous obstacles remain in leveraging big data research to change medical practice. This paper de-scribes the understanding and practical applications of healthcare big data in pedia-tric cancer research, ranging from clinical research design using health insurance big data to medical writing.
Kang, Hyery,Koh, Dong-Yeun,Ahn, Yun-Ho,Jung, Seonghoon,Park, Jaehun,Lee, Jaehyoung,Lee, Huen American Chemical Society 2015 Journal of chemical and engineering data Vol.60 No.2
<P>Terahertz time-domain spectroscopy (THz-TDS) was used to observe the tetrahydrofuran (THF) clathrate hydrate system with dosage of polyvinylpyrrolidone (PVP) with three different average molecular weights (10 000 g/mol, 40 000 g/mol, and 360 000 g/mol). Distinct footprints of phase transition in the THz region (0.4 THz to 2.2 THz) were analyzed and absorption coefficients and complex refractive indices are obtained and compared in the temperature range of 253 to 288 K. Along with the optical properties, ring breathing and stretching modes for different molecular weights of PVP in THF hydrate are analyzed by Raman spectroscopy.</P>
Kim, Hyery,Shin, Donghoon,Kang, Hyoung Jin,Yu, Kyung-Sang,Lee, Ji Won,Kim, Sung Jin,Kim, Min Sun,Song, Eun Sun,Jang, Mi Kyoung,Park, June Dong,Jang, In-Jin,Park, Kyung Duk,Shin, Hee Young,Ahn, Hyo Seo Springer-Verlag 2015 Clinical drug investigation Vol.35 No.7
<P>Empirical antifungal therapy prevents invasive fungal infections in patients with cancer. This study assessed the empirical efficacy of intravenous itraconazole in pediatric patients undergoing hematopoietic stem cell transplantation, and investigated the pharmacokinetics and clinical implications.</P>
Rapid Clathrate Hydrate Formation Using a Heavy Guest Molecule with Sodium Dodecyl Sulfate
Kang, Hyery,Ahn, Yun-Ho,Koh, Dong-Yeun,Baek, Seungjun,Lee, Jae W.,Lee, Huen American Chemical Society 2016 INDUSTRIAL & ENGINEERING CHEMISTRY RESEARCH - Vol.55 No.21
<P>Clathrate hydrates provide porous structures for encaging gas molecules at a high volume ratio (v/v) and can be exploited to improve industrial gas storage and transportation. Direct clathrate hydrate formation from liquid water without mechanical agitation has yielded very low conversion rates due to the mass-transfer limitation between phases. In the present study, the heavy guest molecule of iodomethane was introduced to achieve both rapid clathrate hydrate formation and a high conversion rate. Iodomethane showed full enclathration in water cages in a few minutes and even accelerated the full conversion to a mixed hydrate (sII hydrates) with methane to 1.5 min by renewing liquid-iquid interfaces without mechanical agitation. The interfacial renewal at the growth front will contribute to developing a cost-effective method for natural gas storage and transportation in a clathrate hydrate form.</P>
Kim, Hyery,Seo, Heewon,Park, Yoomi,Min, Byung-Joo,Seo, Myung-Eui,Park, Kyung Duk,Shin, Hee Young,Kim, Ju Han,Kang, Hyoung Jin Korean Cancer Association 2018 Cancer Research and Treatment Vol.50 No.3
<P><B>Purpose</B></P><P>Mercaptopurine (MP) is one of the main chemotherapeutics for acute lymphoblastic leukemia (ALL). To improve treatment outcomes, constant MP dose titration is essential to maintain steady drug exposure, while minimizing myelosuppression. We performed two-stage analyses to identify genetic determinants of MP-related neutropenia in Korean pediatric ALL patients.</P><P><B>Materials and Methods</B></P><P>Targeted sequencing of 40 patients who exhibited definite MP intolerance was conducted using a novel panel of 211 pharmacogenetic-related genes, and subsequent analysis was performed with 185 patients.</P><P><B>Results</B></P><P>Using bioinformatics tools and genetic data, four functionally interesting variants were selected (<I>ABCC4</I>, <I>APEX1</I>, <I>CYP1A1</I>, and <I>CYP4F2</I>). Including four variants, 23 variants in 12 genes potentially linked to MP adverse reactions were selected as final candidates for subsequent analysis in 185 patients. Ultimately, a variant allele in <I>APEX1</I> rs2307486was found to be strongly associated with MP-induced neutropenia that occurred within 28 days of initiating MP (odds ratio, 3.44; p=0.02). Moreover, the cumulative incidence of MP-related neutropenia was significantly higher in patients with <I>APEX1</I> rs2307486 variants, as GG genotypes were associated with the highest cumulative incidence (p < 0.01). <I>NUDT15</I> rs116855232 variants were strongly associated with a higher cumulative incidence of neutropenia (p < 0.01), and a lower median dose of tolerated MP throughout maintenance treatment (p < 0.01).</P><P><B>Conclusion</B></P><P>We have identified that <I>APEX1</I> rs2307486 variants conferred an increased risk of MP-related early onset neutropenia. <I>APEX1</I> and <I>NUDT15</I> both contribute to cell protection from DNA damage or misincorporation, so alleles that impair the function of either gene may affect MP sensitivities, thereby inducing MP-related neutropenia.</P>
Kim, Hyery,Kang, Hyoung Jin,Lee, Ji Won,Park, Kyung Duk,Shin, Hee Young,Ahn, Hyo Seop Springer International 2012 Annals of hematology Vol.91 No.5
<P>Harvesting sufficient progenitor cells from bone marrow (BM) for pediatric patients is a challenging process, especially from smaller donors. Growth factor administration to donors prior to harvest results in an enrichment of the graft and leads to early engraftment. A total of 41 patients received a human leukocyte antigen-identical sibling transplantation using granulocyte colony-stimulating factor (G-CSF)-primed BM. All donors received G-CSF 10?μg/kg/day for 2?days prior to harvest. The median weight difference between donor and recipient was 3.9?kg (range, -29.8 to 32?kg), and the median number of CD34(+) cells harvested was 4.16??10(6)/kg (range, 1.17-31.9??10(6)/kg). The median time to neutrophil engraftment was 12?days (range, 10-27 days), and the time for platelet engraftment was 20?days (range, 12-64 days). The cumulative incidence of acute grade 2 to 3 graft-versus-host disease (GVHD) and chronic GVHD was 4.9% and 5.1%, respectively. An analysis according to the weight difference between donor and recipient showed there was no significant difference in harvested CD34(+) cell dose and in time required for engraftment between smaller and heavier donor recipients. G-CSF-primed BM allows successful engraftment and provides a valuable alternative to unstimulated BM and peripheral blood stem cells with good engraftment and tolerable GVHD even in patients with smaller donors.</P>